The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

31 May 2023 11:51

RNS Number : 1896B
Arix Bioscience Plc
31 May 2023
 

Arix Bioscience plc(the "Company")

PDMR notification & Director Shareholding

The Company today announces it has granted an executive award of nil cost options (the "Award") under the Arix Bioscience plc Executive Incentive Plan (the "Plan") to CEO Robert Lyne, which are subject to performance conditions over a three-year period from 1 January 2023 to 31 December 2025 (the "Performance Period"). The Award takes the form of an option to acquire up to 671,800 ordinary shares of £0.00001 each in the Company. Vested Shares are subject to a further two-year holding period, as set out in the Plan. The performance conditions attached to the Award are set out in the Director's Remuneration Report on page 55 of Company's Annual Report & Accounts 2022.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Robert Lyne

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Arix Bioscience plc

b)

 

LEI

 

213800OVT3AHQCXNIX43

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Arix Bioscience plc Ordinary shares of 0.001 pence each

Identification code

GB00BD045071

b)

 

Nature of the transaction

 

Award of nil-cost options under the Arix Bioscience plc Executive Incentive Plan ("EIP")

 c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

 

 

671,800

d)

 

Aggregated information

- Aggregated volume

N/A (Single Transaction)

- Price

N/A (Single Transaction)

e)

 

Date of the transaction

 

30 May 2023

f)

 

Place of the transaction

 

Outside a trading venue

For further information please contact:Kin Company Secretarial Limited, Company Secretary +44 20 8819 6486

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBFLFXXELEBBB
Date   Source Headline
1st Oct 20202:40 pmEQSLogicBio announces pricing of public offering
21st Sep 202011:20 amEQSHardman & Co Research: Arix Bioscience (ARIX): Realising the valuation disconnect
18th Sep 20208:57 amEQSArix Bioscience PLC: Autolus presents additional AUTO3 data in DLBCL
8th Sep 20207:00 amEQSArix Bioscience PLC: Interim Results for the Six Months Ended 30 June 2020
13th Aug 20207:07 amPRNNotice of Results
10th Aug 202012:49 pmPRNLogicBio announces IND clearance for LB-001
31st Jul 20202:06 pmRNSSecond Price Monitoring Extn
31st Jul 20202:00 pmRNSPrice Monitoring Extension
31st Jul 20207:01 amPRNTotal Voting Rights
20th Jul 20201:28 pmPRNAmplyx announces positive Phase 2 data
10th Jul 20207:53 amPRNAtox Bio plans NDA submission for Q3 2020
8th Jul 20201:27 pmPRNVelosBio completes $137 million Series B financing
1st Jul 20207:00 amPRNDirector/PDMR Shareholding, Issue of Ordinary Shares
1st Jul 20207:00 amPRNDirector/PDMR Shareholding, Issue of Ordinary Shares
12th Jun 20202:24 pmPRNAura presents updated AU-011 clinical data at ARVO 2020
12th Jun 20201:34 pmPRNImara presents positive interim Phase 2a data at EHA
12th Jun 20209:13 amPRNAutolus AUTO1 and AUTO3 data at EHA
8th Jun 20207:08 amPRNArix announces strategic and operational update
4th Jun 20205:42 pmPRNResults of Annual General Meeting
1st Jun 20202:57 pmPRNIterum announces topline Phase 3 data in complicated UTI
29th May 20201:38 pmPRNHarpoon presents interim Phase 1 data for HPN424
29th May 20201:06 pmPRNAutolus presents additional AUTO3 data in DLBCL
27th May 20204:40 pmRNSSecond Price Monitoring Extn
27th May 20204:35 pmRNSPrice Monitoring Extension
20th May 20207:00 amPRNAmplyx closes $53 million Series C extension
19th May 20209:35 amEQSHardman & Co Research: Arix Bioscience (ARIX): 1Q'20 portfolio update
12th May 20207:00 amPRNNotice of Annual General Meeting
28th Apr 20209:23 amPRNPharmaxis announces new data in myelofibrosis
27th Apr 20201:12 pmPRNHarpoon doses first patient in multiple myeloma trial
23rd Apr 20207:30 amEQSHardman & Co Research: Arix Bioscience (ARIX): Resetting the stage
17th Apr 20202:59 pmPRNDirector/PDMR Shareholding
16th Apr 20201:08 pmPRNAutolus announces FDA acceptance of IND application
6th Apr 20207:00 amPRNChanges to Board of Directors and executive leadership
19th Mar 202010:31 amEQSHardman & Co Research: Arix Bioscience (ARIX): Fiscal 2019 - moving with the times
16th Mar 20207:00 amPRNDirector/PDMR Shareholding
12th Mar 20207:11 amPRNImara prices Nasdaq IPO
10th Mar 20207:00 amPRNAnnual Results for the year ended 31 December 2019
9th Mar 202012:00 pmPRNDr Roberto Iacone appointed as EiR
3rd Mar 202012:18 pmPRNUpdate on Imara proposed IPO in the United States
3rd Mar 20207:30 amEQSHardman & Co Research: Q&A with Q&A with Dr Dorothea Hill on Arix Bioscience (ARIX)
27th Feb 202012:00 pmPRNNotice of Results
24th Feb 20201:26 pmPRNAura announces updated Phase 1b/2 clinical data
19th Feb 20207:30 amEQSHardman & Co Research: Arix Bioscience (ARIX) - Initiation of coverage: With high risk can come high reward
17th Feb 20207:00 amPRNImara files for proposed IPO in the United States
30th Jan 202012:08 pmPRNAutolus presents encouraging additional AUTO3 data
27th Jan 20207:00 amPRNArix co-founds Quench Bio with Series A financing
23rd Jan 20207:00 amPRNAutolus announces pricing of public offering
17th Jan 20201:15 pmPRNIterum announces $52 million private placement
18th Dec 201910:00 amPRNPharmaxis business update
17th Dec 201910:57 amPRNBoard changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.